Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Placebo-controlled Double-blind Phase III Trial to Investigate the Reduction of Monthly Migraine Days (MMDs) Over 12 Weeks of Treatment With CGRP mAbs and Onabotulinumtoxin A Intramuscularly Compared With CGRP mAbs and Placebo in Chronic Migraine

NCT07040813 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT07040813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07040813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Placebo-controlled Double-blind Phase III Trial to Investigate the Reduction of Monthly Migraine Days (MMDs) Over 12 Weeks of Treatment With CGRP mAbs and Onabotulinumtoxin A Intramuscularly Compared With CGRP mAbs and Placebo in Chronic Migraine
Lead sponsor
Oslo University Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
June 6, 2025
Completion date
April 30, 2029
Enrollment
450 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic migraine headache, migraine